Description:
Preferred ID: ILX:0109697 Type: term ID# ILX:0109697 Score: 313.24283
Description: A top-down system that manages and controls other cognitive processes, allowing goal-directed behavior.
Preferred ID: CAO:00292 Type: term ID# ILX:0104013 Score: 209.86572
Description: A set of cognitive functions that controls complex, goal-directed thought and behavior. Executive function involves multiple domains, such as CONCEPT FORMATION, goal management, cognitive flexibility, INHIBITION control, and WORKING MEMORY. Impaired executive function is seen in a range of disorders, e.g., SCHIZOPHRENIA; and ADHD.
Preferred ID: MESH:M0526990 Type: term ID# ILX:0737723 Score: 200.82721
Description:
Preferred ID: ILX:0104438 Type: term ID# ILX:0104438 Score: 195.7531
Description:
Preferred ID: ILX:0109942 Type: term ID# ILX:0109942 Score: 195.7531
Description: active maintenance and flexible updating of goal-task relevant information (items, goals, strategies, etc.) in a form that resists interference but has limited capacity. These representations may involve flexible binding of representations, may be characterized by the absence of external support for the internally maintained representations, and are frequently temporary due to ongoing interference
Preferred ID: CAO:00587 Type: term ID# ILX:0112670 Score: 152.63203
Description: A neuropsychological test designed to assess different memory functions. It may incorporate an optional cognitive exam (Brief Cognitive Status Exam) that helps to assess memory related cognitive function.
Preferred ID: MESH:M000620918 Type: term ID# ILX:0430174 Score: 136.13354
Description:
Preferred ID: ILX:0108622 Type: term ID# ILX:0108622 Score: 16.75004
Description: Memory problems (current impact)
Preferred ID: NDA.CDE:2254257 Type: cde ID# CDE:0123816 Score: 11.34172
Description: I. Mentation, Behavior and Mood. Intellectual Impairment
Preferred ID: NDA.CDE:2178662 Type: cde ID# CDE:0298254 Score: 9.64442
Description: A progressive, neurodegenerative disease characterized by loss of function and death of nerve cells in several areas of the brain leading to loss of cognitive function such as memory and language.
Preferred ID: MONDO:0004975 Type: term ID# ILX:0751626 Score: 9.388665
Description: A condition characterized by sudden, temporary, usually short-lived memory loss, not associated with a neurologic disorder. Affected individuals lose memory function for recent events and have a decreased ability to retain new information. It is usually a solitary event.
Preferred ID: MONDO:0001617 Type: term ID# ILX:0766815 Score: 8.107657
Description: To what extent do you consider your sleep problem to INTERFERE with your daily functioning (e.g. daytime fatigue, mood, ability to function at work/daily chores, concentration, memory, mood, etc.) CURRENTLY? PX640801_Insomnia_Interfere_DailyFunctioning
Preferred ID: NDA.CDE:2190587 Type: cde ID# CDE:0166674 Score: 7.199586
Description: To what extent do you consider your sleep problem to INTERFERE with your daily functioning (e.g. daytime fatigue, mood, ability to function at work/daily chores, concentration, memory, mood, etc.) CURRENTLY? PX640801_Insomnia_Interfere_DailyFunctioning
Preferred ID: NDA.CDE:2120685 Type: cde ID# CDE:0250019 Score: 7.028988
Description: is a computer-based cognitive assessment system consisting of a battery of neuropsychological tests, administered to subjects using a touch screen computer. The 22 tests in CANTAB examine various areas of cognitive function, including: * general memory and learning, * working memory and executive function, * visual memory, * attention and reaction time (RT), * semantic-verbal memory, * decision making and response control. The CANTAB endeavours to import the accuracy and rigour of computerised psychological testing whilst retaining the wide range of ability measures demanded of a neuropsychological battery. It is suitable for young and old subjects, and aims to be culture and language independent through the use of non-verbal stimuli in the majority of the tests.
Preferred ID: CAO:00933 Type: term ID# ILX:0101613 Score: 6.773616
Description: A degenerative disease of the brain that causes gradual loss of memory, judgment, and the ability to function socially. About 25% of all Alzheimer disease is familial (more than 2 people in a family have AD). When Alzheimer disease begins before 60 or 65 years of age (early-onset AD) about 60% of the cases are familial (also known as Early-onset familial AD). These cases appear to be inherited in an autosomal dominant manner.
Preferred ID: MONDO:0100087 Type: term ID# ILX:0766224 Score: 4.1235037
Description: Fetal alcohol syndrome (FAS) is a rare malformation syndrome caused by excessive maternal consumption of alcohol during pregnancy. It is characterized by prenatal and/or postnatal growth deficiency (weight and/or height <10th percentile), a unique cluster of minor facial anomalies (short palpebral fissures, flat and smooth philtrum, and thin upper lip) and severe central nervous system (CNS) abnormalities including microcephaly, and cognitive and behavioral impairment (intellectual disability, deficit in general cognition, learning and language, executive function, visual-spatial processing, memory, and attention).
Preferred ID: MONDO:0016011 Type: term ID# ILX:0751646 Score: 3.650727
Description: Minaprine is a psychotropic drug which has proved to be effective in the treatment of various depressive states. Like most antidepressants minaprine antagonizes behavioral despair. Minaprine is an amino-phenylpyridazine antidepressant reported to be relatively free of cardiotoxicity, drowsiness, and weight gain. Pharmacology: Minaprine is an amino-phenylpyridazine antidepressant reported to be relatively free of cardiotoxicity, drowsiness, and weight gain. Similar to other antidepressant treatments, minaprine attenuates the beta-adrenergic receptor function. Studies have also shown that minaprine improves memory consolidation and that repeated drug administration leads to potentiation of this effect. Moreover, the effects of minaprine on memory consolidation are related to its dopaminergic action. Mechanism of action: Minaprine binds to serotonin type 2 receptors and to dopamine D1 and D2 type receptors. It also binds to the serotonin reuptake pump. Therefore, minaprine blocks the reuptake of both dopamine and serotonin. It is also, to a slight degree, cholinomimetic. Thus it may exhibit both mood-brightening and nootropic properties. Drug type: Approved. Small Molecule. Drug category: Antidepressive Agents. Antiparkinson Agents. Central Nervous System Agents
Preferred ID: CHEBI:51038 Type: term ID# ILX:0106983 Score: 2.8021002
Description: Rivastigmine is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer s type. Rivastigmine is a cholinesterase inhibitor that inhibits both butyrylcholinesterase and acetylcholinesterase. Pharmacology: Rivastigmine is a parasympathomimetic and a reversible cholinesterase inhibitor. Rivastigmine is indicated for the treatment of mild to moderate dementia of the Alzheimer's type. Pathological changes in Dementia of the Alzheimer type involve cholinergic neuronal pathways that project from the basal forebrain to the cerebral cortex and hippocampus. These pathways are thought to be intricately involved in memory, attention, learning, and other cognitive processes. While the precise mechanism of rivastigmine's action is unknown, it is postulated to exert its therapeutic effect by enhancing cholinergic function. This is accomplished by increasing the concentration of acetylcholine through reversible inhibition of its hydrolysis by cholinesterase. If this proposed mechanism is correct, rivastigmine's effect may lessen as the disease process advances and fewer cholinergic neurons remain functionally intact. Mechanism of action: Rivastigmine increases the concentration of acetylcholine through reversible inhibition of its hydrolysis by cholinesterase. This acts to enhance cholinergic function. Drug type: Approved. Investigational. Small Molecule. Drug category: Cholinergic Agents. Cholinesterase Inhibitors. Neuroprotective Agents. Nootropic Agents. Parasympathomimetics
Preferred ID: ILX:0110167 Type: term ID# ILX:0110167 Score: 2.6830504
Description: is a subdiscipline of neuroscience which studies the function of neural circuits and systems, most commonly in awake, behaving intact organisms. It is an umbrella term, encompassing a number of areas of study concerned with how nerve cells behave when connected together to form neural networks: vision, for example, or voluntary movement. At this level of analysis, neuroscientists study how different neural circuits analyze sensory information, form perceptions of the external worlds, make decisions, and execute movements. Researchers concerned with systems neuroscience focus on the vast space that exists between molecular and cellular approaches to the brain and the study of high-level mental functions such as language, memory, and self-awareness (which are the purview of behavioral and cognitive neuroscience). Systems neuroscientists typically employ techniques for understanding networks of neurons while they function in vivo (e.g. electrophysiology (single or multi-electrode recording), in vivo imaging, fMRI, PET). The term is commonly used in an educational framework: a common sequence of graduate school neuroscience courses consists of cellular/molecular neuroscience for the first semester, then systems neuroscience for the second semester. It is also sometimes used to distinguish a subdivision within a neuroscience department at an academic institution. - definition adapted from Wikipedia
Preferred ID: NLXINV:100678 Type: term ID# ILX:0111436 Score: 2.5030184